Colorectal Cancer Stage IV Clinical Trial
Official title:
A Randomized, Open, Multicenter Phase III Clinical Trial of Combination of Sintilimab Injection (IBI308) and XELOX+Bevacizumab Compared With XELOX+Bevacizumab as 1st Line Therapy of RAS-Mutant Metastatic Colorectal Cancer
Sintilimab (R&D code: IBI308) is a recombinant human-derived IgG4 type PD-1 monoclonal antibody. PD-1 inhibitor combined with chemotherapy has synergistic effect to further enhance anti-tumor immunity. This study is a phase III clinical study of a three-week regimen of sintilimab combined with the XELOX+ bevacizumab for RAS-mutant metastatic colorectal cancer patients who had not received any treatment before. The purpose of this study is to explore the efficacy of sintilimab combined with XELOX + bevacizumab as first line therapy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03594448 -
Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
|
||
| Active, not recruiting |
NCT03986541 -
AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
|
||
| Completed |
NCT01570452 -
Matrilysin Expression in Different Stages of Colorectal Tumors
|
N/A | |
| Recruiting |
NCT05354817 -
Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin
|
Phase 2 | |
| Recruiting |
NCT05576896 -
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
|
Phase 2 | |
| Completed |
NCT04715061 -
Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments
|
N/A | |
| Terminated |
NCT03149679 -
The p53 Colorectal Cancer Trial
|
Phase 2 | |
| Completed |
NCT05550701 -
Prognostic Impact of Increased Lymph Node Yield in Colorectal Cancer Patients With Synchronous Distant Metastasis: a Population-based Study of the US Database and a Chinese Registry
|
||
| Enrolling by invitation |
NCT04149613 -
Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer
|
||
| Completed |
NCT04425239 -
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT06329700 -
Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy
|
||
| Recruiting |
NCT05382741 -
Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
|
Phase 2 | |
| Recruiting |
NCT06342440 -
Early Detection of Advanced Adenomas and Colorectal Cancer
|
||
| Not yet recruiting |
NCT04917276 -
Treatment Response Prediction System of mCRC Patients Based on CTC
|
||
| Not yet recruiting |
NCT06296056 -
Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care
|
Phase 1 | |
| Recruiting |
NCT04714814 -
Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
|
||
| Not yet recruiting |
NCT05451719 -
Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy
|
Phase 2 | |
| Completed |
NCT03031444 -
Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis
|
Phase 2/Phase 3 | |
| Completed |
NCT05164419 -
Impact de la Marge de résection Sur la Survie à Long Terme et le Taux de récidive Des Patients Atteints de Cancers Colorectaux opérés au CHUS Entre 2006 et 2016 Pour Des métastases hépatiques
|
||
| Recruiting |
NCT05426005 -
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
|
Phase 1/Phase 2 |